Nuveen LLC Takes $6.55 Million Position in Replimune Group, Inc. $REPL

Key Points

• Nuveen LLC has acquired 671,411 shares of Replimune Group, Inc. for approximately $6.5 million, representing an ownership stake of 0.87% as of recently filed documents.
• Institutional investors significantly increased their holdings in Replimune, with some firms like Dimensional Fund Advisors LP and GAMMA Investing LLC growing their positions by 42.7% and 897.2%, respectively.
• Analysts' ratings for Replimune vary, with a consensus "Hold" rating and a price target averaging around $7.67, despite some firms drastically lowering their projections for the stock.

Nuveen LLC purchased a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 671,411 shares of the company's stock, valued at approximately $6,546,000. Nuveen LLC owned 0.87% of Replimune Group as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. US Bancorp DE lifted its stake in Replimune Group by 582.6% during the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after purchasing an additional 3,921 shares during the period. Tower Research Capital LLC TRC grew its stake in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after buying an additional 5,922 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Replimune Group by 106.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company's stock worth $111,000 after buying an additional 5,876 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Replimune Group during the fourth quarter worth about $117,000. Finally, Quantinno Capital Management LP bought a new stake in Replimune Group during the fourth quarter worth about $127,000. Institutional investors own 92.53% of the company's stock.

Insider Activity at Replimune Group

In other news, CFO Emily Luisa Hill sold 9,154 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the sale, the chief financial officer directly owned 134,368 shares of the company's stock, valued at $721,556.16. This represents a 6.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.20% of the stock is currently owned by company insiders.

Replimune Group Trading Down 2.7%

REPL traded down $0.15 during midday trading on Thursday, reaching $5.38. 1,278,059 shares of the company were exchanged, compared to its average volume of 4,001,207. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.94 and a current ratio of 6.94. The stock has a market capitalization of $419.94 million, a P/E ratio of -1.66 and a beta of 0.67. The stock's 50-day simple moving average is $7.54 and its 200 day simple moving average is $9.14. Replimune Group, Inc. has a one year low of $2.68 and a one year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). As a group, analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on REPL shares. Jefferies Financial Group decreased their price objective on shares of Replimune Group from $31.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. BMO Capital Markets cut shares of Replimune Group from an "outperform" rating to an "underperform" rating and decreased their price objective for the stock from $27.00 to $2.00 in a research note on Wednesday, July 23rd. Leerink Partnrs cut shares of Replimune Group from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 22nd. Leerink Partners reaffirmed a "market perform" rating and issued a $3.00 target price (down from $21.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. Finally, Wedbush reaffirmed a "neutral" rating and issued a $4.00 target price (down from $19.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. Two analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $6.50.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.